乳腺癌和卵巢癌患者的髓系肿瘤及其与有害胚系变异的关联
本文提出乳腺癌和卵巢癌患者中髓系肿瘤发生率增高可能部分与潜在胚系癌症易感等位基因相关,而不仅归因于既往抗癌治疗。BRCA1/2、ATM、CHEK2、PALB2等有害胚系变异导致同源重组DNA双链断裂修复缺陷,可能增加新发和治疗相关性髓系肿瘤风险,并可能混杂PARP抑制剂等治疗与治疗相关性髓系肿瘤的关联。
要点
- 乳腺癌和卵巢癌患者髓系肿瘤发生率增高可能部分与胚系癌症易感等位基因相关。
- BRCA1/2等有害胚系变异导致同源重组修复缺陷,可能增加新发和治疗相关性髓系肿瘤风险。
- PARP抑制剂等治疗与治疗相关性髓系肿瘤的关联可能被胚系变异混杂,需更多直接毒性数据。
核心结论
- 乳腺癌和卵巢癌患者中髓系肿瘤发生率增高可能至少部分与潜在胚系癌症易感等位基因相关,而非仅由既往抗癌治疗暴露所致。
研究设计与样本
- 本文为综述,检索范围未报告。
主要发现
- BRCA1/2、ATM、CHEK2、PALB2等相关基因的有害胚系变异导致同源重组DNA双链断裂修复缺陷,使细胞依赖效率较低的修复机制。
- 有害胚系BRCA1/2变异者在无既往抗癌治疗情况下造血系统恶性肿瘤发生率亦增高,提示胚系变异可能增加新发造血系统恶性肿瘤风险。
- PARP抑制剂及其他实体瘤治疗与治疗相关性髓系肿瘤的关联可能被固有的胚系变异混杂,需更多关于这些药物对骨髓功能直接毒性作用的数据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Historically, the increased incidence of myeloid neoplasms observed in individuals with breast and ovarian cancer has been attributed exclusively to prior exposure to cancer-directed therapies. However, as the association between deleterious germline variants and the development of hematopoietic malignancies (HMs) becomes better established, we propose the increased incidence of myeloid neoplasms in those with breast and ovarian cancer may be at least partially related to underlying germline cancer predisposition alleles. Deleterious germline variants in BRCA1/2, ATM, CHEK2, PALB2, and other related genes prevent normal homologous recombination DNA repair of double-strand breaks, leading to reliance on less effective repair mechanisms. This results in a high lifetime risk of breast and ovarian cancer, and likely also increases the risk of subsequent therapy-related myeloid neoplasms (t-MNs). These deleterious germline variants likely increase the risk for de novo HMs as well, as evidenced by the increased incidence of HMs observed in those with deleterious germline BRCA1/2 variants even in the absence of prior cancer-directed therapy. Thus, the association between poly(ADP-ribose) polymerase (PARP) inhibitors and other solid tumor directed therapies and the development of t-MNs may be confounded by the presence of deleterious germline variants which inherently increase the risk of both de novo and t-MNs, and additional data regarding the direct toxic effects of these drugs on bone marrow function are needed.
引用
- Franco S, Godley LA. Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants. Gynecol Oncol. 2024. PMID: 38823308. doi:10.1016/j.ygyno.2024.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。